The Updated World Health Organization Glioma Classification: Cellular and Molecular Origins of Adult Infiltrating Gliomas

Pisapia, David

doi:10.5858/arpa.2016-0493-ra

Cited by 31 publications

(29 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other frequently mutated genes in glioblastomas, such as EGFR and PTEN, displayed similar mutation frequencies as in previous reports [1,3,4,22] , although IDH1, TP53, and ATRX mutations occur more frequently in this glioblastoma cohort ( Figure 2A and Table S3). Additionally, FUBP1, CIC, Notch homolog 1, translocation-associated (Drosophila) (NOTCH1), ATRX, and TP53 mutations were accompanied by IDH1 mutation in GFSCAN LGGs (Figure 2A and Table S3), which is consistent with the results of previous studies [1,3,4]. To summarize, the DIG samples used in the present study showed similar genomic characteristics as an external dataset analyzed in recent studies, indicating that our cohort was relevant and representative, despite the small number of cases.…”

Section: Genomic Profiles Of 72 Digs In the Gfscan Cohortsupporting

confidence: 85%

“…To determine the genomic and expression profiles of 72 DIGs, tissues or cultured GSCs were subjected to whole exome sequencing (WES), glioma-specific targeted DNA sequencing (GliomaSCAN TM ), and whole transcriptome sequencing (WTS) ( Tables S2 and S3). Recently performed large-scale studies reported that the genomic profiles of LGGs and glioblastomas are distinct; glioblastomas show frequent alterations in the epidermal growth factor receptor (EGFR), phosphatase and tensin homolog (PTEN), and cyclin-dependent kinase inhibitor 2A (CDKN2A), whereas genes encoding IDH1/2, ATRX, tumor protein P53 (TP53), capicua transcriptional repressor (CIC), and far upstream element binding protein 1 (FUBP1) are frequently altered in LGGs with or without 1p19q co-deletion [1,3,4,22]. We assessed genomic alterations in these previously reported genes for the 72 DIGs subjected to GFSCAN (Figure 2A and Table S3).…”

Section: Genomic Profiles Of 72 Digs In the Gfscan Cohortmentioning

confidence: 99%

“…Most GSCs from LGGs were included in the E&F-independent group (E&F-independent; n = 14, 73.7% vs. E&F-dependent; n = 5 26.3%) and, consistently, 72% of IDH1-mut GSCs were present in the E&F-independent group. In general, IDH1 mutation is a critical biomarker that is used to classify DIGs into clinically and biologically similar subgroups [3,4]. Mutant IDH is frequent in LGGs but also detected in 50%-88% of secondary glioblastomas and in 5% of primary glioblastomas, resulting in altered 2hydroxyglutarate production and altered DNA methylation [4,22,23].…”

Section: Molecular and Biological Characteristics Of Patient-derived mentioning

confidence: 99%

See 2 more Smart Citations

Sphere-Forming Culture for Expanding Genetically Distinct Patient-Derived Glioma Stem Cells by Cellular Growth Rate Screening

Shin

Cho

et al. 2020

Cancers

View full text Add to dashboard Cite

Diffusely infiltrating gliomas (DIGs) are difficult to completely resect and are associated with a high rate of tumor relapse and progression from low- to high-grade glioma. In particular, optimized short-term culture-enriching patient-derived glioma stem cells (GSCs) are essential for customizing the therapeutic strategy based on clinically feasible in vitro drug screening for a wide range of DIGs, owing to the high inter-tumoral heterogeneity. Herein, we constructed a novel high-throughput culture condition screening platform called ‘GFSCAN’, which evaluated the cellular growth rates of GSCs for each DIG sample in 132 serum-free combinations, using 13 previously reported growth factors closely associated with glioma aggressiveness. In total, 72 patient-derived GSCs with available genomic profiles were tested in GFSCAN to explore the association between cellular growth rates in specific growth factor combinations and genomic/molecular backgrounds, including isocitrate dehydrogenase 1 (IDH1) mutation, chromosome arm 1p and 19q co-deletion, ATRX chromatin remodeler alteration, and transcriptional subtype. GSCs were clustered according to the dependency on epidermal growth factor and basic fibroblast growth factor (E&F), and isocitrate dehydrogenase 1 (IDH1) wild-type GSCs showed higher E&F dependencies than IDH1 mutant GSCs. More importantly, we elucidated optimal combinations for IDH1 mutant glioblastoma and lower grade glioma GSCs with low dependencies on E&F, which could be an aid in clinical decision-making for these DIGs. Thus, we demonstrated the utility of GFSCAN in personalizing in vitro cultivation to nominate personalized therapeutic options, in a clinically relevant time frame, for individual DIG patients, where standard clinical options have been exhausted.

show abstract

Section: Genomic Profiles Of 72 Digs In the Gfscan Cohortsupporting

confidence: 85%

Section: Genomic Profiles Of 72 Digs In the Gfscan Cohortmentioning

confidence: 99%

Section: Molecular and Biological Characteristics Of Patient-derived mentioning

confidence: 99%

See 1 more Smart Citation

Sphere-Forming Culture for Expanding Genetically Distinct Patient-Derived Glioma Stem Cells by Cellular Growth Rate Screening

Shin

Cho

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…SWO-38 cells were less sensitive to WZY-321 compared with SHG-44 cells. The histological subtypes of SHG-44 and SWO-38 cells may explain this sensitivity (27). Therefore, in the subsequent studies, SHG-44 glioma cells were incubated with WZY-321 for 24 h prior to processing the samples for subsequent pharmacological tests.…”

Section: Wzy-321 Induces Cytostatic Effects In Shg-44 and Swo-38mentioning

confidence: 99%

WZY‑321, a novel evodiamine analog, inhibits glioma cell growth in an autophagy‑associated manner

Sun

Zhang²,

Song

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Glioblastoma is one of the most aggressive types of brain tumor. The median survival rate of patients with glioblastoma (World Health Organization grade IV) is <15 months. Therefore, there is an urgent requirement for the development of novel and efficient therapeutic agents against glioma. In previous studies, WZY-321 (10-hydroxy-, a novel evodiamine (Evo) analog, was reported to exhibit enhanced pharmacological properties and improved cytotoxicity against a number of human cancer cell lines compared with Evo. In the current study, the anti-proliferative effect of WZY-321 on SHG-44 and SWO-38 glioma cells was further studied, and its mechanism of action investigated. The results indicated that WZY-321 inhibited the proliferation of SHG-44 cells in a dose-and time-dependent manner by enhancing cellular apoptosis and inducing cell cycle arrest at the G2-M phase. Treatment of glioma cells with WZY-321 concomitantly increased the expression levels of microtubule associated protein 1 light chain 3α and Beclin1, indicating enhanced autophagy. Overall, the results of the present study revealed the anti-proliferative potential of WZY-321 in glioma cells, thus providing a possible autophagy-based therapeutic strategy for the treatment of glioblastoma.

show abstract

“…Human glioma is the most common primary tumor of the central nervous system in adults, representing an unmet clinical challenge as nearly two thirds of them are high-grade lesions with poor outcome (1)(2)(3). Glioma tumors are histologically classified into grades I to IV in the order of increasing malignancy according to the World Health Organization (WHO) criteria (4). Grade IV glioma, accounting for 54% of all human glioma, is the most aggressive and lethal type of brain tumors because of its high invasiveness, robust neovascularization, high relapse after treatments, and recurrence rates (5).…”

Section: Introductionmentioning

confidence: 99%

The Increased Expression of Estrogen-Related Receptor α Correlates with Wnt5a and Poor Prognosis in Patients with Glioma

Zhang

Zhu

Cheng

et al. 2019

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Malignant glioma is an often fatal type of cancer. Elevated expression of the orphan nuclear receptor estrogen-related receptor alpha (ERRa) is an unfavorable factor for malignant progression and poor prognosis in several cancers, although the mechanism by which this receptor affects the pathophysiology of cancers remains obscure. However, few studies have been conducted in regard to the role of ERRa in glioma. In the current study, we found that elevated expression of ERRa was observed in 107 glioma cases by means of IHC. Clinically, high expression of ERRa was associated with later stages of disease progression and clinical outcome of patients with glioma. ERRa had the ability to promote cell proliferation and migration in glioma cell lines. Moreover, in a xenograft model, we also found that silencing ERRa had an inhibitory effect on the growth of glioma. Further investigation confirmed that ERRa was involved in the carcinogenesis of glioma via the regulation of the Wnt5a signal pathway in vitro and in vivo. Our study was first to show the overexpression of ERRa in glioma tissues and a direct correlation between ERRa expression and clinical prognosis of glioma. Together, these data reveal that ERRa has prognostic significance in glioma, and targeting ERRa may provide a reliable therapeutic strategy for the treatment for human glioma.

show abstract

The Updated World Health Organization Glioma Classification: Cellular and Molecular Origins of Adult Infiltrating Gliomas

Cited by 31 publications

References 126 publications

Sphere-Forming Culture for Expanding Genetically Distinct Patient-Derived Glioma Stem Cells by Cellular Growth Rate Screening

Sphere-Forming Culture for Expanding Genetically Distinct Patient-Derived Glioma Stem Cells by Cellular Growth Rate Screening

WZY‑321, a novel evodiamine analog, inhibits glioma cell growth in an autophagy‑associated manner

The Increased Expression of Estrogen-Related Receptor α Correlates with Wnt5a and Poor Prognosis in Patients with Glioma

Contact Info

Product

Resources

About